{
    "clinical_study": {
        "@rank": "33618", 
        "acronym": "DasaCBF", 
        "arm_group": {
            "arm_group_label": "dasatinib", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "In patients with Core Binding Factors Acute Myelogenous Leukemia, the level of Minimal\n      Residual Disease after chemotherapy is predictive of relapse. The relapse risk is also\n      increased in case of mutations of receptors tyrosine kinase. For patients with a high\n      Minimal Residual Disease  level at the end of consolidation or in molecular relapse,\n      maintenance by the inhibitor dasatinib is proposed."
        }, 
        "brief_title": "Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia", 
        "condition": "Acute Myelogenous Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient presenting de novo or secondary Core Binding Factors Acute Myelogenous\n             Leukemia\n\n          -  Patient in first and presenting one of following criteria:\n\n          -  \"Resistant\" Patient: decrease of less than 3 log of the Acute Myelogenous Leukemia\n             transcript level in the bone marrow after 2 consolidations\n\n          -  Patient in \" molecular relapse \": increase of of more than 1 log of the Core Acute\n             Myelogenous Leukemia transcript level on two successive marrow samples\n\n        Exclusion Criteria:\n\n          -  Woman of childbearing potential\n\n          -  Concurrent incurable malignacy other than Acute Myelogenous Leukemia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "27", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02113319", 
            "org_study_id": "CHUpromoteur2006-08"
        }, 
        "intervention": {
            "arm_group_label": "dasatinib", 
            "description": "dasatinib 50 mg and 20 mg During one year", 
            "intervention_name": "dasatinib", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Dasatinib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Core Binding Factors", 
            "Acute Myelogenous Leukemia refractory to conventional chemotherapy", 
            "molecular relapse"
        ], 
        "lastchanged_date": "April 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Angers", 
                    "country": "France", 
                    "zip": "49 933"
                }, 
                "name": "University Hospital"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label, Multicenter, Phase II Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia Refractory to Conventional Chemotherapy or in Molecular Relapse. Intergroupe Fran\u00e7ais Des leuc\u00e9mie aigu\u00eb my\u00e9loblastique", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
            "measure": "measure relapse-free survival", 
            "safety_issue": "No", 
            "time_frame": "4 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02113319"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University Hospital, Angers", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Angers", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2007", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "January 2009"
    }
}